Adrabetadex Approved for Infantile-Onset Niemann-Pick C
FDA approved adrabetadex as the first therapy reported to improve survival in infantile-onset Niemann-Pick disease type C. Median survival was 8.5 versus 4.9 years and reported risk of death was 55% lower, based on matched external controls rather than a randomized trial; a boxed warning for potentially permanent hearing loss makes monitoring essential.
Sources (3)
Updated Nov 20, 2026